The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX

Journal of Hepatology

Volumn 49, Issue 3, 2008, Pages 373-383

  Aderca, Ileana ^a   Moser, Catherine D ^a   Veerasamy, Manivannan ^a   Bani Hani, Ahmad H ^a   Bonilla Guerrero, Ruben ^a   Ahmed, Kadra ^a   Shire, Abdirashid ^a   Cazanave, Sophie C ^a   Montoya, Damian P ^a   Mettler, Teresa A ^a   Burgart, Lawrence J ^a   Nagorney, David M ^c   Thibodeau, Stephen N ^b   Cunningham, Julie M ^b   Lai, Jin Ping ^a   Roberts, Lewis R ^a  

^a MAYO CLINIC CANCER CENTER   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Apoptosis; Hepatocellular carcinoma; JNK; WWOX

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; MESSENGER RNA; OXIDOREDUCTASE; SMALL INTERFERING RNA; SP 600129; STAUROSPORINE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WW DOMAIN CONTAINING OXIDOREDUCTASE;

ADULT; AGED; ALLELIC IMBALANCE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CHROMOSOME 16; CHROMOSOME LOSS; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; PRIMARY TUMOR; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 16; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIVER NEOPLASMS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 8; OXIDOREDUCTASES; RNA, MESSENGER; STAUROSPORINE; TUMOR SUPPRESSOR PROTEINS;

EID: 48449090284     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.05.015     Document Type: Article

References (79)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. El-Serag H.B., and Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 (2007) 2557-2576
3. Llovet RSJ, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S, Poulin-Costello M. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial), ASCO Annual Meeting 2007; 2007.
4. Yamada T., De Souza A.T., Finkelstein S., and Jirtle R.L. Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci USA 94 (1997) 10351-10355
5. Yuan B.Z., Keck-Waggoner C., Zimonjic D.B., Thorgeirsson S.S., and Popescu N.C. Alterations of the FHIT gene in human hepatocellular carcinoma. Cancer Res 60 (2000) 1049-1053
6. Kishimoto Y., Morisawa T., Kitano M., Shiota G., Horie Y., Suou T., et al. Loss of heterozygosity of the mannose 6-phosphate/insulin-like growth factor II receptor and p53 genes in human hepatocellular carcinoma. Hepatol Res 20 (2001) 68-83
7. Oka Y., Waterland R.A., Killian J.K., Nolan C.M., Jang H.S., Tohara K., et al. M6P/IGF2R tumor suppressor gene mutated in hepatocellular carcinomas in Japan. Hepatology 35 (2002) 1153-1163
8. Denison S.R., Callahan G., Becker N.A., Phillips L.A., and Smith D.I. Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer. Genes Chromosomes Cancer 38 (2003) 40-52
9. Wang F., Denison S., Lai J.P., Philips L.A., Montoya D., Kock N., et al. Parkin gene alterations in hepatocellular carcinoma. Genes Chromosomes Cancer 40 (2004) 85-96
10. Balsara B.R., Pei J., De Rienzo A., Simon D., Tosolini A., Lu Y.Y., et al. Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1. Genes Chromosomes Cancer 30 (2001) 245-253
11. Yakicier M.C., Legoix P., Vaury C., Gressin L., Tubacher E., Capron F., et al. Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma. Oncogene 20 (2001) 5232-5238
12. Krummel K.A., Roberts L.R., Kawakami M., Glover T.W., and Smith D.I. The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations. Genomics 69 (2000) 37-46
13. Paige A.J., Taylor K.J., Stewart A., Sgouros J.G., Gabra H., Sellar G.C., et al. A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. Cancer Res 60 (2000) 1690-1697
14. Bednarek A.K., Laflin K.J., Daniel R.L., Liao Q., Hawkins K.A., and Aldaz C.M. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 60 (2000) 2140-2145
15. Krummel K.A., Denison S.R., Calhoun E., Phillips L.A., and Smith D.I. The common fragile site FRA16D and its associated gene WWOX are highly conserved in the mouse at Fra8E1. Genes Chromosomes Cancer 34 (2002) 154-167
16. O'Keefe L.V., and Richards R.I. Common chromosomal fragile sites and cancer: focus on FRA16D. Cancer Lett 232 (2006) 37-47
17. Ried K., Finnis M., Hobson L., Mangelsdorf M., Dayan S., Nancarrow J.K., et al. Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum Mol Genet 9 (2000) 1651-1663
18. Nunez M.I., Ludes-Meyers J., and Aldaz C.M. WWOX protein expression in normal human tissues. J Mol Histol 37 (2006) 115-125
19. Bednarek A.K., Keck-Waggoner C.L., Daniel R.L., Laflin K.J., Bergsagel P.L., Kiguchi K., et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 61 (2001) 8068-8073
20. Chang N.S., Doherty J., Ensign A., Schultz L., Hsu L.J., and Hong Q. WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53. J Biol Chem 280 (2005) 43100-43108
21. Driouch K., Prydz H., Monese R., Johansen H., Lidereau R., and Frengen E. Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene 21 (2002) 1832-1840
22. Guler G., Uner A., Guler N., Han S.Y., Iliopoulos D., Hauck W.W., et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer 100 (2004) 1605-1614
23. Guler G., Uner A., Guler N., Han S.Y., Iliopoulos D., McCue P., et al. Concordant loss of fragile gene expression early in breast cancer development. Pathol Int 55 (2005) 471-478
24. Iliopoulos D., Fabbri M., Druck T., Qin H.R., Han S.Y., and Huebner K. Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of Wwox expression. Clin Cancer Res 13 (2007) 268-274
25. Iliopoulos D., Guler G., Han S.Y., Johnston D., Druck T., McCorkell K.A., et al. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 24 (2005) 1625-1633
26. van Wezel T., Lombaerts M., van Roon E.H., Philippo K., Baelde H.J., Szuhai K., et al. Expression analysis of candidate breast tumour suppressor genes on chromosome 16q. Breast Cancer Res 7 (2005) R998-R1004
27. Gourley C., Paige A.J., Taylor K.J., Scott D., Francis N.J., Rush R., et al. WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear. Int J Oncol 26 (2005) 1681-1689
28. Nunez M.I., Rosen D.G., Ludes-Meyers J.H., Abba M.C., Kil H., Page R., et al. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer 5 (2005) 64
29. Paige A.J., Taylor K.J., Taylor C., Hillier S.G., Farrington S., Scott D., et al. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci USA 98 (2001) 11417-11422
30. Chang N.S., Schultz L., Hsu L.J., Lewis J., Su M., and Sze C.I. 17beta-Estradiol upregulates and activates WOX1/WWOXv1 and WOX2/WWOXv2 in vitro: potential role in cancerous progression of breast and prostate to a premetastatic state in vivo. Oncogene 24 (2005) 714-723
31. Qin H.R., Iliopoulos D., Semba S., Fabbri M., Druck T., Volinia S., et al. A role for the WWOX gene in prostate cancer. Cancer Res 66 (2006) 6477-6481
32. Watson J.E., Doggett N.A., Albertson D.G., Andaya A., Chinnaiyan A., van Dekken H., et al. Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer. Oncogene 23 (2004) 3487-3494
33. Pimenta F.J., Gomes D.A., Perdigao P.F., Barbosa A.A., Romano-Silva M.A., Gomez M.V., et al. Characterization of the tumor suppressor gene WWOX in primary human oral squamous cell carcinomas. Int J Cancer 118 (2006) 1154-1158
34. Pimenta F.J., Cordeiro G.T., Pimenta L.G., Viana M.B., Lopes J., Gomez M.V., et al. Molecular alterations in the tumor suppressor gene WWOX in oral leukoplakias. Oral Oncol (2007) [Epub ahead of print] PMID: 18061530
35. Aqeilan R.I., Kuroki T., Pekarsky Y., Albagha O., Trapasso F., Baffa R., et al. Loss of WWOX expression in gastric carcinoma. Clin Cancer Res 10 (2004) 3053-3058
36. Kuroki T., Tajima Y., Furui J., and Kanematsu T. Common fragile genes and digestive tract cancers. Surg Today 36 (2006) 1-5
37. Kuroki T., Yendamuri S., Trapasso F., Matsuyama A., Aqeilan R.I., Alder H., et al. The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res 10 (2004) 2459-2465
38. Kuroki T., Trapasso F., Shiraishi T., Alder H., Mimori K., Mori M., et al. Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res 62 (2002) 2258-2260
39. Lai F.J., Cheng C.L., Chen S.T., Wu C.H., Hsu L.J., Lee J.Y., et al. WOX1 is essential for UVB irradiation-induced apoptosis and down-regulated via translational blockade in UVB-induced cutaneous squamous cell carcinoma in vivo. Clin Cancer Res 11 (2005) 5769-5777
40. Ishii H., Mimori K., Inageta T., Murakumo Y., Vecchione A., Mori M., et al. Components of DNA damage checkpoint pathway regulate UV exposure-dependent alterations of gene expression of FHIT and WWOX at chromosome fragile sites. Mol Cancer Res 3 (2005) 130-138
41. O'Keefe L.V., Liu Y., Perkins A., Dayan S., Saint R., and Richards R.I. FRA16D common chromosomal fragile site oxido-reductase (FOR/WWOX) protects against the effects of ionizing radiation in Drosophila. Oncogene 24 (2005) 6590-6596
42. Thavathiru E., Ludes-Meyers J.H., MacLeod M.C., and Aldaz C.M. Expression of common chromosomal fragile site genes, WWOX/FRA16D and FHIT/FRA3B is downregulated by exposure to environmental carcinogens, UV, and BPDE but not by IR. Mol Carcinog 44 (2005) 174-182
43. Dias E.P., Pimenta F.J., Sarquis M.S., Dias Filho M.A., Aldaz C.M., Fujii J.B., et al. Association between decreased WWOX protein expression and thyroid cancer development. Thyroid 17 (2007) 1055-1059
44. Cantor J.P., Iliopoulos D., Rao A.S., Druck T., Semba S., Han S.Y., et al. Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity. Int J Cancer 120 (2007) 24-31
45. Donati V., Fontanini G., Dell'omodarme M., Prati M.C., Nuti S., Lucchi M., et al. WWOX expression in different histologic types and subtypes of non-small cell lung cancer. Clin Cancer Res 13 (2007) 884-891
46. Fabbri M., Iliopoulos D., Trapasso F., Aqeilan R.I., Cimmino A., Zanesi N., et al. WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci U S A 102 (2005) 15611-15616
47. Yendamuri S., Kuroki T., Trapasso F., Henry A.C., Dumon K.R., Huebner K., et al. WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res 63 (2003) 878-881
48. Zhou Y., Xu Y., and Zhang Z. Deletion and mutation of WWOX exons 6-8 in human non-small cell lung cancer. J Huazhong Univ Sci Technol Med Sci 25 (2005) 162-165
49. Aarhus M., Bruland O., Bredholt G., Lybaek H., Husebye E.S., Krossnes B.K., et al. Microarray analysis reveals down-regulation of the tumour suppressor gene WWOX and up-regulation of the oncogene TYMS in intracranial sporadic meningiomas. J Neurooncol (2008)
50. Ishii H., Vecchione A., Furukawa Y., Sutheesophon K., Han S.Y., Druck T., et al. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol Cancer Res 1 (2003) 940-947
51. Alsop A.E., Taylor K., Zhang J., Gabra H., Paige A.J., and Edwards P.A. Homozygous deletions may be markers of nearby heterozygous mutations: the complex deletion at FRA16D in the HCT116 colon cancer cell line removes exons of WWOX. Genes Chromosomes Cancer 47 (2008) 437-447
52. Ludes-Meyers J.H., Bednarek A.K., Popescu N.C., Bedford M., and Aldaz C.M. WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet Genome Res 100 (2003) 101-110
53. Aqeilan R.I., Trapasso F., Hussain S., Costinean S., Marshall D., Pekarsky Y., et al. Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci USA 104 (2007) 3949-3954
54. Philipp-Staheli J., Payne S.R., and Kemp C.J. p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 264 (2001) 148-168
55. Zanesi N., Fidanza V., Fong L.Y., Mancini R., Druck T., Valtieri M., et al. The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci USA 98 (2001) 10250-10255
56. Kannangai R., Sahin F., Adegbola O., Ashfaq R., Su G.H., and Torbenson M. FHIT mRNA and protein expression in hepatocellular carcinoma. Mod Pathol 17 (2004) 653-659
57. Chang N.S. A potential role of p53 and WOX1 in mitochondrial apoptosis (review). Int J Mol Med 9 (2002) 19-24
58. Chang N.S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B., et al. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem 276 (2001) 3361-3370
59. Chang N.S., Doherty J., and Ensign A. JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis. J Biol Chem 278 (2003) 9195-9202
60. Chen S.T., Chuang J.I., Cheng C.L., Hsu L.J., and Chang N.S. Light-induced retinal damage involves tyrosine 33 phosphorylation, mitochondrial and nuclear translocation of WW domain-containing oxidoreductase in vivo. Neuroscience 130 (2005) 397-407
61. Park S.W., Ludes-Meyers J., Zimonjic D.B., Durkin M.E., Popescu N.C., and Aldaz C.M. Frequent downregulation and loss of WWOX gene expression in human hepatocellular carcinoma. Br J Cancer 91 (2004) 753-759
62. Jiang J., Gusev Y., Aderca I., Mettler T.A., Nagorney D.M., Brackett D.J., et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 14 (2008) 419-427
63. Lai J.P., Chien J.R., Moser D.R., Staub J.K., Aderca I., Montoya D.P., et al. hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology 126 (2004) 231-248
64. Watanabe A., Hippo Y., Taniguchi H., Iwanari H., Yashiro M., Hirakawa K., et al. An opposing view on WWOX protein function as a tumor suppressor. Cancer Res 63 (2003) 8629-8633
65. Shimoyama Y., Gotoh M., Ino Y., Sakamoto M., Kato K., and Hirohashi S. Characterization of high-molecular-mass forms of basic fibroblast growth factor produced by hepatocellular carcinoma cells: possible involvement of basic fibroblast growth factor in hepatocarcinogenesis. Jpn J Cancer Res 82 (1991) 1263-1270
66. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98 (2001) 13681-13686
67. Lai J.P., Sandhu D.S., Yu C., Han T., Moser C.D., Jackson K.K., et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 47 (2008) 1211-1222
68. Lai J., Chien J., Staub J., Avula R., Greene E.L., Matthews T.A., et al. Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 278 (2003) 23107-23117
69. Mahajan N.P., Whang Y.E., Mohler J.L., and Earp H.S. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Res 65 (2005) 10514-10523
70. Frixen U.H., Behrens J., Sachs M., Eberle G., Voss B., Warda A., et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113 (1991) 173-185
71. Shimoyama Y., and Hirohashi S. Cadherin intercellular adhesion molecule in hepatocellular carcinomas: loss of E-cadherin expression in an undifferentiated carcinoma. Cancer Lett 57 (1991) 131-135
72. Nishida N., Fukuda Y., Kokuryu H., Sadamoto T., Isowa G., Honda K., et al. Accumulation of allelic loss on arms of chromosomes 13q, 16q and 17p in the advanced stages of human hepatocellular carcinoma. Int J Cancer 51 (1992) 862-868
73. Nishida N., Fukuda Y., Komeda T., Ito T., Nishimura T., Minata M., et al. Prognostic impact of multiple allelic losses on metastatic recurrence in hepatocellular carcinoma after curative resection. Oncology 62 (2002) 141-148
74. Fiorentino M., Altimari A., Ravaioli M., Gruppioni E., Gabusi E., Corti B., et al. Predictive value of biological markers for hepatocellular carcinoma patients treated with orthotopic liver transplantation. Clin Cancer Res 10 (2004) 1789-1795
75. Schwabe R.F., Bradham C.A., Uehara T., Hatano E., Bennett B.L., Schoonhoven R., et al. c-Jun-N-terminal kinase drives cyclin D1 expression and proliferation during liver regeneration. Hepatology 37 (2003) 824-832
76. Czaja M.J. The future of GI and liver research: editorial perspectives. III. JNK/AP-1 regulation of hepatocyte death. Am J Physiol Gastrointest Liver Physiol 284 (2003) G875-G879
77. Bae M.A., and Song B.J. Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells. Mol Pharmacol 63 (2003) 401-408
78. Gunawan B.K., Liu Z.X., Han D., Hanawa N., Gaarde W.A., and Kaplowitz N. c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology 131 (2006) 165-178
79. Henderson N.C., Pollock K.J., Frew J., Mackinnon A.C., Flavell R.A., Davis R.J., et al. Critical role of c-jun (NH2) terminal kinase in paracetamol-induced acute liver failure. Gut 56 (2007) 982-990